# TScan Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tscan-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.tscan.com
- Total disclosed funding: $158M
- Latest round: Series C (Jan 15, 2021)
- Investors on record: 10

## About

Founded in 2018 and based in Massachusetts, US, TScan Therapeutics, Inc. is a biopharmaceutical company focusing on the development of T-cell receptors (TCR) for the treatment of cancer and tumors. The company was founded by Lea Hachigian and Tomasz Kula. David Southwell serves as the CEO of TScan Therapeutics, Inc. In December 2024, TScan Therapeutics, Inc. raised USD 30 million in venture funding from other unspecified investors.

The company's product uses the target ID platform to identify the natural targets of tumor-reactive T cells and identify therapeutically active TCRs. TCR-T therapies are being developed by TScan Therapeutics for the treatment of hematological and solid tumors. In 2017, the FDA approved the CAR T-cell therapies tisagenlecleucel (KymriahTM) and axicabtagene ciloleucel (YescartaTM) for the treatment of B-cell acute lymphoblastic leukemia and large B-cell lymphoma in patients with B-cell acute lymphoblastic leukemia. In April 2024, TScan Therapeutics, Inc. raised USD 150 million in a private placement, selling 2.47 million shares at USD 7.13 per share on the Nasdaq Global Select Market under the ticker symbol "TCRX". TScan Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 3.16 million shares of common stock as part of the listing.

The company will use the 2024 funding for further growth and development.

## Funding rounds

- Series C, Jan 15, 2021, $100M — Pitango, Novartis Venture Fund, Bessemer Venture Partners, GV, Longwood Fund, BlackRock, RA Capital Management, 6 Dimensions Capital
- Series B, Jan 9, 2020, $35M — Pitango, Novartis Venture Fund, Astellas Venture Management, Bessemer Venture Partners, GV, Longwood Fund, 6 Dimensions Capital, Novartis Institute for Biomedical Research
- Series B, Jul 24, 2019, $23M — Novartis Venture Fund, Bessemer Venture Partners, GV, Longwood Fund, Novartis Institute for Biomedical Research

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series C
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series B, Series C
- Novartis Institute for Biomedical Research — Series B
- Pitango (https://capitalatlas.ai/funds/pitango) — Series B, Series C
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B, Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C